SEC Form 4 · accession 0001179110-15-000377
KYTHERA BIOPHARMACEUTICALS INC · KYTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nathaniel E David
Director
Period of report
Jan 2, 2015
Accepted (ET)
Jan 5, 2015 · 7:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001436304
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jan 2, 2015 | S | 1,016 | $35.20 | D | 483,781 | D | |
| Common StockF3 | Jan 2, 2015 | S | 424 | $35.69 | D | 483,357 | D | |
| Common Stock | Jan 2, 2015 | S | 240 | $35.00 | D | 483,117 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan which expires April 30, 2015.
- F2The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $34.61 to $35.54, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $35.59 to $35.80, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.